Tag: chronic plaque psoriasis
February 28, 2017
Lilly to Present New Data for Taltz (ixekizumab)
At the 75th annual meeting of the American Academy of Dermatology (AAD), Lilly (NYSE:LLY) will share new data on its... January 10, 2017
Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab (HUMIRA)... January 6, 2017
Dermira Provides Corporate Update
Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of... January 3, 2017
Dermira Initiates Phase 3 Clinical Program in Acne
Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of... December 19, 2016
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis
Cellceutix Corporation is pleased to announce today that 24 of the 25 (all US based) core Phase 2b clinical trial... December 8, 2016
UCB and Dermira Announce Second CIMZIA® Phase 3 Trial Meets Co-Primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
UCB and Dermira today announced topline results from CIMPASI-1, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and... November 29, 2016